Combining cancerous and non-cancerous cell patterns, the AI model evaluates breast cancer outcomes better than expert pathologists.
List view / Grid view
Researchers have developed an AI based model that is 80 percent accurate in predicting the therapy outcome of high-grade ovarian cancer.
Percent necrosis calculated with machine learning model for patients with osteosarcoma provides an accurate prognosis for survival.
29 September 2023 | By Analytik Jena
Watch this webinar to learn how PROTACs are revolutionising drug discovery, and the critical role protein purification plays in the production of therapeutic proteins.
This ebook outlines Euretos’ approach to target discovery and indication expansion.
24 August 2023 | By Bio-Rad Laboratories Inc.
Watch our industry experts to learn about the tangible benefits and best practice of custom flow cytometry automation projects. You’ll discover how to reduce your challenges implementing tailored automation, controlling the quality of the data produced and improving the reliability of your data acquisition.
Researchers from the German Cancer Research Center (DKFZ) and the Cambridge Stem Cell Institute have developed an artificial intelligence (AI) system capable of identifying and characterising white and red blood cells within microscopic images of blood samples. This AI algorithm holds the potential to aid medical professionals in diagnosing blood…
La Jolla biologists harness machine learning and computational tools to make sense of immune system data.
Tune in to this episode to hear experts discussing the hot topic that is AI and how AI technology is used in drug discovery, looking specifically at how Biotechs & Pharma are trying to keep up with emerging technology.
Machine learning (ML) presents a promising opportunity to revolutionize early cancer detection in primary care, addressing the challenges associated with diagnostic errors and improving patient outcomes. The potential of ML in this field is highlighted in a recent paper published in Oncoscience
This article is the second part of Drug Target Review’s Izzy Wood’s discussion with Olivia Cavlan, Chief Corporate Development and Strategy Officer at Alchemab Therapeutics Ltd, exploring the role of AI in target discovery, its applications in personalised medicine, and the evolving landscape of pharmaceutical development.
In this interview Drug Target Review’s Izzy Wood and Olivia Cavlan, Chief Corporate Development and Strategy Officer at Alchemab Therapeutics Ltd, uncover the untapped potential of AI in target discovery. Alchemab’s revolutionary platform aims to identify common antibodies in resilient individuals and uncover the antigens that contribute to their disease-fighting…